UTI(UTI)
UTI
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E | FY2028E | FY2029E |
|---|---|---|---|---|
| Revenue Avg | $910M | $992M | $1.08B | $1.19B |
| Low | $909M | $990M | $1.08B | $1.19B |
| High | $911M | $993M | $1.09B | $1.19B |
| EBITDA Avg | $207M | $225M | $247M | $271M |
| Low | $207M | $225M | $246M | $270M |
| High | $207M | $226M | $247M | $271M |
| EBIT Avg | $165M | $180M | $197M | $216M |
| Low | $165M | $180M | $196M | $215M |
| High | $165M | $180M | $197M | $216M |
| Net Income Avg | $43M | $47M | $78M | $108M |
| Low | $41M | $47M | $77M | $108M |
| High | $44M | $47M | $80M | $109M |
| EPS Avg | $0.77 | $0.85 | $1.41 | $1.95 |
| Low | $0.74 | $0.85 | $1.39 | $1.94 |
| High | $0.79 | $0.85 | $1.43 | $1.96 |
| Analysts (Rev / EPS) | 5 / 5 | 5 / 5 | 2 / 2 | 1 / 1 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 |
|---|---|---|---|---|---|
| Revenue Avg | $248M | $239M | $241M | $240M | $271M |
| Low | $246M | $237M | $239M | $238M | $269M |
| High | $250M | $241M | $243M | $242M | $273M |
| EBITDA Avg | $56M | $54M | $55M | $55M | $62M |
| Low | $56M | $54M | $54M | $54M | $61M |
| High | $57M | $55M | $55M | $55M | $62M |
| EBIT Avg | $45M | $43M | $44M | $44M | $49M |
| Low | $45M | $43M | $43M | $43M | $49M |
| High | $45M | $44M | $44M | $44M | $50M |
| Net Income Avg | $29M | $10M | $6M | $7M | $24M |
| Low | $26M | $10M | $6M | $7M | $24M |
| High | $30M | $10M | $6M | $7M | $24M |
| EPS Avg | $0.52 | $0.18 | $0.11 | $0.13 | $0.43 |
| Low | $0.48 | $0.18 | $0.11 | $0.13 | $0.42 |
| High | $0.54 | $0.18 | $0.12 | $0.13 | $0.43 |
| Analysts (Rev / EPS) | 4 / 4 | 3 / 2 | 3 / 2 | 2 / 1 | 2 / 1 |